Subscribe to Newsletter
Subspecialties Cornea / Ocular Surface, Health Economics and Policy, Business and Innovation

Ready, Steady, Graft

The first cultivated autologous limbal epithelial cell transplantation (CALEC) has been performed in the US. The technique, developed in 2018 by researchers at Harvard Medical School (HMS), Massachusetts Eye and Ear, Boston Children’s Hospital, and Dana-Farber Cancer Institute, was used to treat four patients with chemically induced corneal injuries. CALEC uses a patient’s limbal stem cells – found at the outer border of the cornea – to create an ocular graft. The cells are processed in a clean room environment to maintain maximum sterility over a period of approximately three weeks, at which point the graft is ready for transplantation. Ula Jurkunas, Associate Professor of Ophthalmology at HMS and Associate Scientist at the Schepens Eye Research Institute, has been working on the technique for more than a decade.

“Using the patient’s own stem cells is a big step for regenerative medicine,” said Jurkunas (1). “With this clinical trial, we hope to pave the way for better care for patients with corneal blindness.” The only treatment options currently available for patients with chemical burns are corneal transplantation – which carries risk of infection and the development of glaucoma – or conjunctival limbal autograft, which involves transplanting a portion of healthy corneal cells directly onto the affected area.

Jurkunas considers CALEC to be an ideal alternative because it carries no risk of rejection and does not require patients to take steroids or immunosuppressive medications. The patients who received the CALEC graft reported no pain, confirming the technique’s feasibility and allowing researchers to begin the second phase of the trial, which will continue through 2021.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Harvard Medical School (2020). Available at:
About the Author
Phoebe Harkin

Associate Editor of The Ophthalmologist

I’ve always loved telling stories. So much so, I decided to make a job of it. I finished a Masters in Magazine Journalism and spent three years working as a creative copywriter before itchy feet sent me (back)packing. It took seven months and 13 countries, but I’m now happily settled on The Ophthalmologist, where I’m busy getting stuck into all things eyeballs.

Related Case Studies
The Missing Piece of the Dry Eye Puzzle

| Contributed by Quidel

Uncovering Ocular Comorbidity

| Contributed by Quidel

Finding Ocular Surface Inflammation

| Contributed by Quidel

Related Product Profiles
Subspecialties Cornea / Ocular Surface
Tear Osmolarity – Empowering. Established. Essential.

| Contributed by TearLab

Subspecialties Cornea / Ocular Surface
Preservative-Free Cyclosporine 0.1% Ophthalmic Emulsion

| Contributed by ImprimisRx

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: